Melanotan II Research: Melanocortin Receptors and Evidence

Melanotan II for research is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH), classified by the IUPHAR/BPS Guide to Pharmacology as a full agonist at human MC1R, MC3R, MC4R and MC5R receptors; it is supplied strictly for laboratory research use only and is not approved for administration to humans or animals [4].

The IUPHAR/BPS listing records Melanotan II under the peptide-ligand identifier MT-II, with high-affinity potency values reported across all four receptor subtypes [4]. That receptor breadth is the defining pharmacological feature of MT-II as a research tool: because MT-II engages multiple melanocortin receptors rather than a single target, mechanistic conclusions drawn from any experiment depend on which receptor subtype and tissue preparation are under study. A 1996 PubMed-indexed pilot study described MT-II as a cyclic heptapeptide analogue and documented measurable biological signals in three healthy male volunteers following subcutaneous administration, including pigmentation change [1]. That study remains one of the few indexed human pharmacology records for the compound, which underlines both the research interest in MT-II and the narrow human-evidence base available to date.

Reading this article, you will learn how MT-II is classified across the melanocortin receptor family and what that breadth means for experimental design; what the published human and preclinical evidence actually shows, and where its limits lie; and how to interpret batch-specific analytical documentation such as HPLC purity and certificates of analysis.

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of α-MSH, classified by the IUPHAR/BPS Guide to Pharmacology as a full agonist at human MC1R, MC3R, MC4R and MC5R receptors, supplied strictly for laboratory research use and not approved for administration to humans or animals [4].

The IUPHAR/BPS listing records the compound under the peptide-ligand identifier MT-II, with the synonym melanotan II, and reports high-affinity potency values across all four receptor subtypes [4]. That breadth across the melanocortin receptor family is the defining pharmacological feature of MT-II as a research tool: mechanistic conclusions from any experiment depend on which receptor subtype and tissue preparation are under study. A 1996 PubMed-indexed pilot study defined MT-II as a cyclic heptapeptide analogue and documented measurable biological signals in three healthy male volunteers following subcutaneous administration, including pigmentation change [1].

Analytical documentation for MT-II research material typically includes HPLC-UV (high-performance liquid chromatography with ultraviolet detection) purity data and mass-spectrometry identity confirmation, both of which are batch-specific. Understanding what HPLC purity does and does not prove is necessary before treating a purity percentage as complete identity evidence, and researchers should verify a CoA against their batch number on receipt.

The strongest direct evidence for Melanotan II in research is biological activity at melanocortin receptors, confirmed across animal models and a small human pilot study. Evidence separates into three tiers: one human trial, several rodent studies, and receptor-pharmacology data from authoritative databases.

Human Evidence

A 1996 phase-I pilot study in three healthy male volunteers administered MT-II subcutaneously and reported increased pigmentation alongside dose-related adverse effects including nausea, fatigue, and Grade II somnolence at a single dose of 0.03 mg/kg [1]. Because the trial enrolled three participants, it establishes that MT-II produces measurable pharmacological signals in people at that dose, not that those signals are therapeutically beneficial or reproducible across broader populations [1].

Preclinical Evidence

Rodent studies extend the evidence base beyond pigmentation. A 2019 study published in PMC found that MT-II microinjected into the nucleus accumbens reduced food intake and appetitive responding without producing conditioned taste avoidance or measurable change in metabolic rate, supporting a central melanocortin role in feeding circuitry [2]. Earlier rat work reported that MT-II promoted peripheral nerve regeneration and exhibited neuroprotective properties [2]. Both findings are animal-model observations and do not establish clinical outcomes in people.

Receptor-Pharmacology Data

IUPHAR/BPS classifies MT-II as a full agonist at human MC1R, MC3R, MC4R and MC5R, with reported potency values in the high-affinity range across those receptor subtypes [4]. That classification derives from in vitro binding and functional assay data, not from human clinical outcomes.

Melanotan II and PT-141 are related but distinct research compounds: Melanotan II is a non-selective synthetic melanocortin-receptor agonist with documented full-agonist activity at MC1R, MC3R, MC4R and MC5R in human receptor assays, whereas PT-141 is an alternative name for bremelanotide, a separate drug candidate developed along a different pharmacological pathway [1]. The IUPHAR/BPS Guide to Pharmacology lists Melanotan II under the ligand identifier MT-II and does not treat it as synonymous with bremelanotide [1].

The practical distinction for researchers is receptor scope and development context. Melanotan II is characterised in the primary pharmacology literature as a broad melanocortin agonist studied across multiple receptor subtypes and tissue contexts, including pigmentation, feeding circuitry and peripheral nerve models [1][2]. Bremelanotide has a separate regulatory and clinical development history that falls outside the scope of Melanotan II research documentation.

For researchers assessing catalogue format and specification differences between the two compounds, the PT-141 research pen page provides the relevant product-level detail, and the PT-141 versus Melanotan II comparison sets the two compounds side by side.

Batch certificates of analysis for Melanotan II research material carry explicit RUO declarations stating the compound is not for human or veterinary use and does not constitute a medicinal product, food supplement, cosmetic or medical device. That classification defines the intended-use boundary for laboratory procurement: the material is supplied for in vitro and preclinical mechanistic study, not for administration to people or animals. Researchers should treat the RUO designation as a condition of supply, not as a quality grade or regulatory approval.

The practical implication for laboratory teams is that Melanotan II research material is appropriate for receptor-binding assays, cell-based signalling studies and the kind of preclinical feeding or neuroprotection work documented in the published literature [2][4]. Compounding, self-administration or any protocol involving human subjects outside a formally approved clinical framework falls outside the permitted scope of supply.

Before beginning any assay, confirm that the batch certificate number matches the vial in hand and review the storage and stability guidance for research peptides to maintain sample integrity from receipt through use. To review available MT-II research material specifications or request a certificate of analysis for a specific batch, visit the Melanotan II research pen page or Veyvora’s research-peptide catalogue.